Sign Out
BLEOMYCIN SULFATE can cause fetal harm when administered to a pregnant woman. It has been shown to be teratogenic in rats (intraperitoneal administration). Pregnant women or women of childbearing potential should be advised to avoid becoming pregnant during therapy with Bleomycin sulfate.
It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued by women receiving Bleomycin sulfate therapy. Safety and effectiveness of Bleomycin sulfate in pediatric patients have not been established.
Continue with Google